Avid Bioservices Inc (CDMO)

[sulaco]

CP, here's your money quote from that article


American Association of Cancer Research 8/19/2013 article (Thorpe)

AACR Thorpe 8/19/2013 link

Bavituximab, the human chimeric version of 2aG4, in combination with chemotherapy, is being used to treat patients with cancer in randomized clinical trials (38–40). Impressive
antitumor effects in patients with cancer have been obtained
with other antibodies that enhance tumor immunity, including
anti-PD1, anti-PD-1L, and ipilimumab (anti-CTLA-4; ref. 50).
Unlike these antibodies, which inhibit negative feedback pathways
in immune cell activation, bavituximab seems to act by
reversing the immunosuppressive effects of exposed phosphatidylserine in the tumor microenvironment, resulting in activation of local tumor immunity and damage to tumor
vasculature.

It's nice to see the Board review the science a bit more instead of all the emotion. Thanks to CP, Geo, and a few others.

Thorpe is laying it all out here. He KNOWS that anti-XYZ are effective. He also knows that Bavi is in an a priori immunological position in relation to these downstream players.

I agree with CP. It's only a matter of time before our Big-Bang. The science is all there...and it's indispensable to the tumor microenvironment to address phosphatidylserine.


OK, that's my post for the day.

GLTAL,

Joe